Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 12/20 | 0.42 |
| ▸ | NPY1R | P25929 | 8/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.42 |
| ▸ | NPY2R | P49146 | 5/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24900018 | 1.00 | SIRT5 (0.49) | SIRT5ALBSIRT6SIRT1NPY4R | |
| SCHEMBL15987249 | 0.94 | SIRT5 (0.57) | SIRT5ALBSIRT6SIRT1NPY4R | |
| SCHEMBL16045801 | 0.94 | SIRT5 (0.57) | SIRT5ALBSIRT6SIRT1NPY4R | |
| SCHEMBL14615959 | 0.93 | SIRT6 (0.44) | SIRT5ALBSIRT6SIRT1NPY4R | |
| Trifluoroacetic Acid SCHEMBL8526715 | 0.90 | NPY4R (0.48) | SIRT5ALBSIRT6SIRT1NPY4R | |
| SCHEMBL468901 | 0.89 | FOLH1 (0.49) | SIRT5ALBSIRT6SIRT1NPY4R | |
| SCHEMBL446929 | 0.89 | FOLH1 (0.49) | SIRT5ALBSIRT6SIRT1NPY4R | |
| SCHEMBL6026003 | 0.89 | FOLH1 (0.49) | SIRT5ALBSIRT6SIRT1NPY4R | |
| SCHEMBL30526285 | 0.89 | FOLH1 (0.49) | SIRT5ALBSIRT6SIRT1NPY4R | |
| SCHEMBL31024641 | 0.88 | SIRT6 (0.57) | SIRT5ALBSIRT6SIRT1NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9445992-B2 | Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion | ARISGEN SA (CH) | 2016-09-20 | — | — | US | claimed |
| US-20120302502-A1 | MUCOSAL DELIVERY COMPOSITIONS COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION | ARISGEN SA (CH) | 2012-11-29 | — | — | US | claimed |
| EP-2504019-A2 | MUCOSAL DELIVERY COMPOSITION COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION | ArisGen SA (CH) | 2012-10-03 | — | — | EP | claimed |
| WO-2011064316-A2 | MUCOSAL DELIVERY OF PEPTIDES | BOTTI PAOLO (CH) | 2011-06-03 | — | — | WO | claimed |
| WO-2022129627-A1 | OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS | PHI PHARMA SA (CH) | 2022-06-23 | — | — | WO | disclosed |
| EP-4015004-A1 | PROTEOGLYCAN SPECIFIC BRANCHED PEPTIDES | Phi Pharma SA (CH) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022052014-A1 | CLASS OF PLATINUM COMPOUNDS FOR TREATING CANCER, AND METHOD FOR PREPARATION THEREOF | 上海海聚生物科技有限公司 | 2022-03-17 | — | — | WO | disclosed |
| US-20200048367-A1 | N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE TO REDUCE THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-9533048-B2 | Mucosal delivery of drugs | ARISGEN SA (CH) | 2017-01-03 | — | — | US | disclosed |
| US-9445992-B2 | Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion | ARISGEN SA (CH) | 2016-09-20 | — | — | US | disclosed |
| EP-2714088-B1 | MUCOSAL DELIVERY OF DRUGS | ARISGEN SA (CH) | 2015-11-25 | — | — | EP | disclosed |
| US-20140187489-A1 | MUCOSAL DELIVERY OF DRUGS | ARISGEN SA (CH) | 2014-07-03 | — | — | US | disclosed |
| WO-2012160203-A1 | MUCOSAL DELIVERY OF DRUGS | ARISGEN SA (CH) | 2012-11-29 | — | — | WO | disclosed |
| US-20120302502-A1 | MUCOSAL DELIVERY COMPOSITIONS COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION | ARISGEN SA (CH) | 2012-11-29 | — | — | US | disclosed |
| EP-2504019-A2 | MUCOSAL DELIVERY COMPOSITION COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION | ArisGen SA (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011064316-A2 | MUCOSAL DELIVERY OF PEPTIDES | BOTTI PAOLO (CH) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302502-A1 | MUCOSAL DELIVERY COMPOSITIONS COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION | VIP, CFTR, IAPP | SIRT5 4663/4885ALB 2394/4885SIRT6 3744/4885 |
| US-20200048367-A1 | N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE TO REDUCE THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES | ARGLU1, PNISR, DNPEP | SIRT5 1090/4885ALB 144/4885SIRT6 421/4885 |
| US-20140187489-A1 | MUCOSAL DELIVERY OF DRUGS | SGMS1, SGMS2, CETP | SIRT5 2884/4885ALB 1872/4885SIRT6 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.